カテゴリー： 世界, 医療/バイオ, QYResearch

統合失調症関連ペプチドの世界市場インサイト・予測（～2028年）

【英語タイトル】Global Schizophrenia Related Peptide Market Insights, Forecast to 2028

QYResearchが出版した調査資料（QY22JLX10486）・商品コード：QY22JLX10486
・発行会社（調査会社）：QYResearch
・発行日：2022年7月（※2025年版があります。お問い合わせください。）
・ページ数：79
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

COVID-19のパンデミックにより、統合失調症関連ペプチドのグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に統合失調症関連ペプチドの世界市場のxxx％を占める「0.95」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「科学研究」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
統合失調症関連ペプチドの中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの統合失調症関連ペプチド市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

統合失調症関連ペプチドのグローバル主要企業には、Peptide Institute、LifeTein、Biorbyt、Novatein Biosciencesなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

統合失調症関連ペプチド市場は、種類と用途によって区分されます。世界の統合失調症関連ペプチド市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
0.95、0.99

【用途別セグメント】
科学研究、医療、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 統合失調症関連ペプチド製品概要
- 種類別市場（0.95、0.99）
- 用途別市場（科学研究、医療、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の統合失調症関連ペプチド販売量予測2017-2028
- 世界の統合失調症関連ペプチド売上予測2017-2028
- 統合失調症関連ペプチドの地域別販売量
- 統合失調症関連ペプチドの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別統合失調症関連ペプチド販売量
- 主要メーカー別統合失調症関連ペプチド売上
- 主要メーカー別統合失調症関連ペプチド価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（0.95、0.99）
- 統合失調症関連ペプチドの種類別販売量
- 統合失調症関連ペプチドの種類別売上
- 統合失調症関連ペプチドの種類別価格
・用途別市場規模（科学研究、医療、その他）
- 統合失調症関連ペプチドの用途別販売量
- 統合失調症関連ペプチドの用途別売上
- 統合失調症関連ペプチドの用途別価格
・北米市場
- 北米の統合失調症関連ペプチド市場規模（種類別、用途別）
- 主要国別の統合失調症関連ペプチド市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの統合失調症関連ペプチド市場規模（種類別、用途別）
- 主要国別の統合失調症関連ペプチド市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の統合失調症関連ペプチド市場規模（種類別、用途別）
- 主要国別の統合失調症関連ペプチド市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の統合失調症関連ペプチド市場規模（種類別、用途別）
- 主要国別の統合失調症関連ペプチド市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの統合失調症関連ペプチド市場規模（種類別、用途別）
- 主要国別の統合失調症関連ペプチド市場規模（トルコ、サウジアラビア）
・企業情報
Peptide Institute、LifeTein、Biorbyt、Novatein Biosciences
・産業チェーン及び販売チャネル分析
- 統合失調症関連ペプチドの産業チェーン分析
- 統合失調症関連ペプチドの原材料
- 統合失調症関連ペプチドの生産プロセス
- 統合失調症関連ペプチドの販売及びマーケティング
- 統合失調症関連ペプチドの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 統合失調症関連ペプチドの産業動向
- 統合失調症関連ペプチドのマーケットドライバー
- 統合失調症関連ペプチドの課題
- 統合失調症関連ペプチドの阻害要因
・主な調査結果

Market Analysis and Insights: Global Schizophrenia Related Peptide Market
Due to the COVID-19 pandemic, the global Schizophrenia Related Peptide market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, 0.95 accounting for % of the Schizophrenia Related Peptide global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Scientific Research segment is altered to an % CAGR throughout this forecast period.
China Schizophrenia Related Peptide market size is valued at US$ million in 2021, while the US and Europe Schizophrenia Related Peptide are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Schizophrenia Related Peptide landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Schizophrenia Related Peptide include Peptide Institute, LifeTein, Biorbyt and Novatein Biosciences, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Schizophrenia Related Peptide Scope and Segment
Schizophrenia Related Peptide market is segmented by Purity and by Application. Players, stakeholders, and other participants in the global Schizophrenia Related Peptide market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Purity and by Application for the period 2017-2028.
Segment by Purity
0.95
0.99
Segment by Application
Scientific Research
Medical
Others
By Company
Peptide Institute
LifeTein
Biorbyt
Novatein Biosciences
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Schizophrenia Related Peptide Product Introduction
1.2 Market by Purity
1.2.1 Global Schizophrenia Related Peptide Market Size Growth Rate by Purity, 2017 VS 2021 VS 2028
1.2.2 0.95
1.2.3 0.99
1.3 Market by Application
1.3.1 Global Schizophrenia Related Peptide Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Scientific Research
1.3.3 Medical
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Schizophrenia Related Peptide Sales Estimates and Forecasts 2017-2028
2.2 Global Schizophrenia Related Peptide Revenue Estimates and Forecasts 2017-2028
2.3 Global Schizophrenia Related Peptide Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Schizophrenia Related Peptide Sales by Region
2.4.1 Global Schizophrenia Related Peptide Sales by Region (2017-2022)
2.4.2 Global Sales Schizophrenia Related Peptide by Region (2023-2028)
2.5 Global Schizophrenia Related Peptide Revenue by Region
2.5.1 Global Schizophrenia Related Peptide Revenue by Region (2017-2022)
2.5.2 Global Schizophrenia Related Peptide Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Schizophrenia Related Peptide Sales by Manufacturers
3.1.1 Global Top Schizophrenia Related Peptide Manufacturers by Sales (2017-2022)
3.1.2 Global Schizophrenia Related Peptide Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Schizophrenia Related Peptide in 2021
3.2 Global Schizophrenia Related Peptide Revenue by Manufacturers
3.2.1 Global Schizophrenia Related Peptide Revenue by Manufacturers (2017-2022)
3.2.2 Global Schizophrenia Related Peptide Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Schizophrenia Related Peptide Revenue in 2021
3.3 Global Schizophrenia Related Peptide Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Schizophrenia Related Peptide Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Schizophrenia Related Peptide Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Purity
4.1 Global Schizophrenia Related Peptide Sales by Purity
4.1.1 Global Schizophrenia Related Peptide Historical Sales by Purity (2017-2022)
4.1.2 Global Schizophrenia Related Peptide Forecasted Sales by Purity (2023-2028)
4.1.3 Global Schizophrenia Related Peptide Sales Market Share by Purity (2017-2028)
4.2 Global Schizophrenia Related Peptide Revenue by Purity
4.2.1 Global Schizophrenia Related Peptide Historical Revenue by Purity (2017-2022)
4.2.2 Global Schizophrenia Related Peptide Forecasted Revenue by Purity (2023-2028)
4.2.3 Global Schizophrenia Related Peptide Revenue Market Share by Purity (2017-2028)
4.3 Global Schizophrenia Related Peptide Price by Purity
4.3.1 Global Schizophrenia Related Peptide Price by Purity (2017-2022)
4.3.2 Global Schizophrenia Related Peptide Price Forecast by Purity (2023-2028)
5 Market Size by Application
5.1 Global Schizophrenia Related Peptide Sales by Application
5.1.1 Global Schizophrenia Related Peptide Historical Sales by Application (2017-2022)
5.1.2 Global Schizophrenia Related Peptide Forecasted Sales by Application (2023-2028)
5.1.3 Global Schizophrenia Related Peptide Sales Market Share by Application (2017-2028)
5.2 Global Schizophrenia Related Peptide Revenue by Application
5.2.1 Global Schizophrenia Related Peptide Historical Revenue by Application (2017-2022)
5.2.2 Global Schizophrenia Related Peptide Forecasted Revenue by Application (2023-2028)
5.2.3 Global Schizophrenia Related Peptide Revenue Market Share by Application (2017-2028)
5.3 Global Schizophrenia Related Peptide Price by Application
5.3.1 Global Schizophrenia Related Peptide Price by Application (2017-2022)
5.3.2 Global Schizophrenia Related Peptide Price Forecast by Application (2023-2028)
6 North America
6.1 North America Schizophrenia Related Peptide Market Size by Purity
6.1.1 North America Schizophrenia Related Peptide Sales by Purity (2017-2028)
6.1.2 North America Schizophrenia Related Peptide Revenue by Purity (2017-2028)
6.2 North America Schizophrenia Related Peptide Market Size by Application
6.2.1 North America Schizophrenia Related Peptide Sales by Application (2017-2028)
6.2.2 North America Schizophrenia Related Peptide Revenue by Application (2017-2028)
6.3 North America Schizophrenia Related Peptide Market Size by Country
6.3.1 North America Schizophrenia Related Peptide Sales by Country (2017-2028)
6.3.2 North America Schizophrenia Related Peptide Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Schizophrenia Related Peptide Market Size by Purity
7.1.1 Europe Schizophrenia Related Peptide Sales by Purity (2017-2028)
7.1.2 Europe Schizophrenia Related Peptide Revenue by Purity (2017-2028)
7.2 Europe Schizophrenia Related Peptide Market Size by Application
7.2.1 Europe Schizophrenia Related Peptide Sales by Application (2017-2028)
7.2.2 Europe Schizophrenia Related Peptide Revenue by Application (2017-2028)
7.3 Europe Schizophrenia Related Peptide Market Size by Country
7.3.1 Europe Schizophrenia Related Peptide Sales by Country (2017-2028)
7.3.2 Europe Schizophrenia Related Peptide Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Schizophrenia Related Peptide Market Size by Purity
8.1.1 Asia Pacific Schizophrenia Related Peptide Sales by Purity (2017-2028)
8.1.2 Asia Pacific Schizophrenia Related Peptide Revenue by Purity (2017-2028)
8.2 Asia Pacific Schizophrenia Related Peptide Market Size by Application
8.2.1 Asia Pacific Schizophrenia Related Peptide Sales by Application (2017-2028)
8.2.2 Asia Pacific Schizophrenia Related Peptide Revenue by Application (2017-2028)
8.3 Asia Pacific Schizophrenia Related Peptide Market Size by Region
8.3.1 Asia Pacific Schizophrenia Related Peptide Sales by Region (2017-2028)
8.3.2 Asia Pacific Schizophrenia Related Peptide Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Schizophrenia Related Peptide Market Size by Purity
9.1.1 Latin America Schizophrenia Related Peptide Sales by Purity (2017-2028)
9.1.2 Latin America Schizophrenia Related Peptide Revenue by Purity (2017-2028)
9.2 Latin America Schizophrenia Related Peptide Market Size by Application
9.2.1 Latin America Schizophrenia Related Peptide Sales by Application (2017-2028)
9.2.2 Latin America Schizophrenia Related Peptide Revenue by Application (2017-2028)
9.3 Latin America Schizophrenia Related Peptide Market Size by Country
9.3.1 Latin America Schizophrenia Related Peptide Sales by Country (2017-2028)
9.3.2 Latin America Schizophrenia Related Peptide Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Schizophrenia Related Peptide Market Size by Purity
10.1.1 Middle East and Africa Schizophrenia Related Peptide Sales by Purity (2017-2028)
10.1.2 Middle East and Africa Schizophrenia Related Peptide Revenue by Purity (2017-2028)
10.2 Middle East and Africa Schizophrenia Related Peptide Market Size by Application
10.2.1 Middle East and Africa Schizophrenia Related Peptide Sales by Application (2017-2028)
10.2.2 Middle East and Africa Schizophrenia Related Peptide Revenue by Application (2017-2028)
10.3 Middle East and Africa Schizophrenia Related Peptide Market Size by Country
10.3.1 Middle East and Africa Schizophrenia Related Peptide Sales by Country (2017-2028)
10.3.2 Middle East and Africa Schizophrenia Related Peptide Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Peptide Institute
11.1.1 Peptide Institute Corporation Information
11.1.2 Peptide Institute Overview
11.1.3 Peptide Institute Schizophrenia Related Peptide Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Peptide Institute Schizophrenia Related Peptide Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Peptide Institute Recent Developments
11.2 LifeTein
11.2.1 LifeTein Corporation Information
11.2.2 LifeTein Overview
11.2.3 LifeTein Schizophrenia Related Peptide Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 LifeTein Schizophrenia Related Peptide Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 LifeTein Recent Developments
11.3 Biorbyt
11.3.1 Biorbyt Corporation Information
11.3.2 Biorbyt Overview
11.3.3 Biorbyt Schizophrenia Related Peptide Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Biorbyt Schizophrenia Related Peptide Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Biorbyt Recent Developments
11.4 Novatein Biosciences
11.4.1 Novatein Biosciences Corporation Information
11.4.2 Novatein Biosciences Overview
11.4.3 Novatein Biosciences Schizophrenia Related Peptide Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Novatein Biosciences Schizophrenia Related Peptide Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novatein Biosciences Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Schizophrenia Related Peptide Industry Chain Analysis
12.2 Schizophrenia Related Peptide Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Schizophrenia Related Peptide Production Mode & Process
12.4 Schizophrenia Related Peptide Sales and Marketing
12.4.1 Schizophrenia Related Peptide Sales Channels
12.4.2 Schizophrenia Related Peptide Distributors
12.5 Schizophrenia Related Peptide Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Schizophrenia Related Peptide Industry Trends
13.2 Schizophrenia Related Peptide Market Drivers
13.3 Schizophrenia Related Peptide Market Challenges
13.4 Schizophrenia Related Peptide Market Restraints
14 Key Findings in The Global Schizophrenia Related Peptide Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Schizophrenia Related Peptide Market Size Growth Rate by Purity, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of 0.95
Table 3. Major Manufacturers of 0.99
Table 4. Global Schizophrenia Related Peptide Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Schizophrenia Related Peptide Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Schizophrenia Related Peptide Sales by Region (2017-2022) & (K Units)
Table 7. Global Schizophrenia Related Peptide Sales Market Share by Region (2017-2022)
Table 8. Global Schizophrenia Related Peptide Sales by Region (2023-2028) & (K Units)
Table 9. Global Schizophrenia Related Peptide Sales Market Share by Region (2023-2028)
Table 10. Global Schizophrenia Related Peptide Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Schizophrenia Related Peptide Revenue Market Share by Region (2017-2022)
Table 12. Global Schizophrenia Related Peptide Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Schizophrenia Related Peptide Revenue Market Share by Region (2023-2028)
Table 14. Global Schizophrenia Related Peptide Sales by Manufacturers (2017-2022) & (K Units)
Table 15. Global Schizophrenia Related Peptide Sales Share by Manufacturers (2017-2022)
Table 16. Global Schizophrenia Related Peptide Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Schizophrenia Related Peptide Revenue Share by Manufacturers (2017-2022)
Table 18. Schizophrenia Related Peptide Price by Manufacturers (2017-2022) &(US$/Unit)
Table 19. Global Schizophrenia Related Peptide Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Schizophrenia Related Peptide by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Schizophrenia Related Peptide as of 2021)
Table 21. Schizophrenia Related Peptide Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Schizophrenia Related Peptide Product Offered
Table 23. Date of Manufacturers Enter into Schizophrenia Related Peptide Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Schizophrenia Related Peptide Sales by Purity (2017-2022) & (K Units)
Table 26. Global Schizophrenia Related Peptide Sales by Purity (2023-2028) & (K Units)
Table 27. Global Schizophrenia Related Peptide Sales Share by Purity (2017-2022)
Table 28. Global Schizophrenia Related Peptide Sales Share by Purity (2023-2028)
Table 29. Global Schizophrenia Related Peptide Revenue by Purity (2017-2022) & (US$ Million)
Table 30. Global Schizophrenia Related Peptide Revenue by Purity (2023-2028) & (US$ Million)
Table 31. Global Schizophrenia Related Peptide Revenue Share by Purity (2017-2022)
Table 32. Global Schizophrenia Related Peptide Revenue Share by Purity (2023-2028)
Table 33. Schizophrenia Related Peptide Price by Purity (2017-2022) & (US$/Unit)
Table 34. Global Schizophrenia Related Peptide Price Forecast by Purity (2023-2028) & (US$/Unit)
Table 35. Global Schizophrenia Related Peptide Sales by Application (2017-2022) & (K Units)
Table 36. Global Schizophrenia Related Peptide Sales by Application (2023-2028) & (K Units)
Table 37. Global Schizophrenia Related Peptide Sales Share by Application (2017-2022)
Table 38. Global Schizophrenia Related Peptide Sales Share by Application (2023-2028)
Table 39. Global Schizophrenia Related Peptide Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Schizophrenia Related Peptide Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Schizophrenia Related Peptide Revenue Share by Application (2017-2022)
Table 42. Global Schizophrenia Related Peptide Revenue Share by Application (2023-2028)
Table 43. Schizophrenia Related Peptide Price by Application (2017-2022) & (US$/Unit)
Table 44. Global Schizophrenia Related Peptide Price Forecast by Application (2023-2028) & (US$/Unit)
Table 45. North America Schizophrenia Related Peptide Sales by Purity (2017-2022) & (K Units)
Table 46. North America Schizophrenia Related Peptide Sales by Purity (2023-2028) & (K Units)
Table 47. North America Schizophrenia Related Peptide Revenue by Purity (2017-2022) & (US$ Million)
Table 48. North America Schizophrenia Related Peptide Revenue by Purity (2023-2028) & (US$ Million)
Table 49. North America Schizophrenia Related Peptide Sales by Application (2017-2022) & (K Units)
Table 50. North America Schizophrenia Related Peptide Sales by Application (2023-2028) & (K Units)
Table 51. North America Schizophrenia Related Peptide Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Schizophrenia Related Peptide Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Schizophrenia Related Peptide Sales by Country (2017-2022) & (K Units)
Table 54. North America Schizophrenia Related Peptide Sales by Country (2023-2028) & (K Units)
Table 55. North America Schizophrenia Related Peptide Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Schizophrenia Related Peptide Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Schizophrenia Related Peptide Sales by Purity (2017-2022) & (K Units)
Table 58. Europe Schizophrenia Related Peptide Sales by Purity (2023-2028) & (K Units)
Table 59. Europe Schizophrenia Related Peptide Revenue by Purity (2017-2022) & (US$ Million)
Table 60. Europe Schizophrenia Related Peptide Revenue by Purity (2023-2028) & (US$ Million)
Table 61. Europe Schizophrenia Related Peptide Sales by Application (2017-2022) & (K Units)
Table 62. Europe Schizophrenia Related Peptide Sales by Application (2023-2028) & (K Units)
Table 63. Europe Schizophrenia Related Peptide Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Schizophrenia Related Peptide Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Schizophrenia Related Peptide Sales by Country (2017-2022) & (K Units)
Table 66. Europe Schizophrenia Related Peptide Sales by Country (2023-2028) & (K Units)
Table 67. Europe Schizophrenia Related Peptide Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Schizophrenia Related Peptide Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Schizophrenia Related Peptide Sales by Purity (2017-2022) & (K Units)
Table 70. Asia Pacific Schizophrenia Related Peptide Sales by Purity (2023-2028) & (K Units)
Table 71. Asia Pacific Schizophrenia Related Peptide Revenue by Purity (2017-2022) & (US$ Million)
Table 72. Asia Pacific Schizophrenia Related Peptide Revenue by Purity (2023-2028) & (US$ Million)
Table 73. Asia Pacific Schizophrenia Related Peptide Sales by Application (2017-2022) & (K Units)
Table 74. Asia Pacific Schizophrenia Related Peptide Sales by Application (2023-2028) & (K Units)
Table 75. Asia Pacific Schizophrenia Related Peptide Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Schizophrenia Related Peptide Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Schizophrenia Related Peptide Sales by Region (2017-2022) & (K Units)
Table 78. Asia Pacific Schizophrenia Related Peptide Sales by Region (2023-2028) & (K Units)
Table 79. Asia Pacific Schizophrenia Related Peptide Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Schizophrenia Related Peptide Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Schizophrenia Related Peptide Sales by Purity (2017-2022) & (K Units)
Table 82. Latin America Schizophrenia Related Peptide Sales by Purity (2023-2028) & (K Units)
Table 83. Latin America Schizophrenia Related Peptide Revenue by Purity (2017-2022) & (US$ Million)
Table 84. Latin America Schizophrenia Related Peptide Revenue by Purity (2023-2028) & (US$ Million)
Table 85. Latin America Schizophrenia Related Peptide Sales by Application (2017-2022) & (K Units)
Table 86. Latin America Schizophrenia Related Peptide Sales by Application (2023-2028) & (K Units)
Table 87. Latin America Schizophrenia Related Peptide Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Schizophrenia Related Peptide Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Schizophrenia Related Peptide Sales by Country (2017-2022) & (K Units)
Table 90. Latin America Schizophrenia Related Peptide Sales by Country (2023-2028) & (K Units)
Table 91. Latin America Schizophrenia Related Peptide Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Schizophrenia Related Peptide Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Schizophrenia Related Peptide Sales by Purity (2017-2022) & (K Units)
Table 94. Middle East and Africa Schizophrenia Related Peptide Sales by Purity (2023-2028) & (K Units)
Table 95. Middle East and Africa Schizophrenia Related Peptide Revenue by Purity (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Schizophrenia Related Peptide Revenue by Purity (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Schizophrenia Related Peptide Sales by Application (2017-2022) & (K Units)
Table 98. Middle East and Africa Schizophrenia Related Peptide Sales by Application (2023-2028) & (K Units)
Table 99. Middle East and Africa Schizophrenia Related Peptide Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Schizophrenia Related Peptide Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Schizophrenia Related Peptide Sales by Country (2017-2022) & (K Units)
Table 102. Middle East and Africa Schizophrenia Related Peptide Sales by Country (2023-2028) & (K Units)
Table 103. Middle East and Africa Schizophrenia Related Peptide Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Schizophrenia Related Peptide Revenue by Country (2023-2028) & (US$ Million)
Table 105. Peptide Institute Corporation Information
Table 106. Peptide Institute Description and Major Businesses
Table 107. Peptide Institute Schizophrenia Related Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 108. Peptide Institute Schizophrenia Related Peptide Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Peptide Institute Recent Developments
Table 110. LifeTein Corporation Information
Table 111. LifeTein Description and Major Businesses
Table 112. LifeTein Schizophrenia Related Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 113. LifeTein Schizophrenia Related Peptide Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. LifeTein Recent Developments
Table 115. Biorbyt Corporation Information
Table 116. Biorbyt Description and Major Businesses
Table 117. Biorbyt Schizophrenia Related Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 118. Biorbyt Schizophrenia Related Peptide Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Biorbyt Recent Developments
Table 120. Novatein Biosciences Corporation Information
Table 121. Novatein Biosciences Description and Major Businesses
Table 122. Novatein Biosciences Schizophrenia Related Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 123. Novatein Biosciences Schizophrenia Related Peptide Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Novatein Biosciences Recent Developments
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Schizophrenia Related Peptide Distributors List
Table 128. Schizophrenia Related Peptide Customers List
Table 129. Schizophrenia Related Peptide Market Trends
Table 130. Schizophrenia Related Peptide Market Drivers
Table 131. Schizophrenia Related Peptide Market Challenges
Table 132. Schizophrenia Related Peptide Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Schizophrenia Related Peptide Product Picture
Figure 3. Global Schizophrenia Related Peptide Market Share by Purity in 2021 & 2028
Figure 3. 0.95 Product Picture
Figure 4. 0.99 Product Picture
Figure 5. Global Schizophrenia Related Peptide Market Share by Application in 2021 & 2028
Figure 6. Scientific Research
Figure 7. Medical
Figure 8. Others
Figure 9. Schizophrenia Related Peptide Report Years Considered
Figure 10. Global Schizophrenia Related Peptide Sales 2017-2028 (K Units)
Figure 11. Global Schizophrenia Related Peptide Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Schizophrenia Related Peptide Revenue 2017-2028 (US$ Million)
Figure 13. Global Schizophrenia Related Peptide Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 14. Global Schizophrenia Related Peptide Sales Market Share by Region (2017-2022)
Figure 15. Global Schizophrenia Related Peptide Sales Market Share by Region (2023-2028)
Figure 16. North America Schizophrenia Related Peptide Sales YoY (2017-2028) & (K Units)
Figure 17. North America Schizophrenia Related Peptide Revenue YoY (2017-2028) & (US$ Million)
Figure 18. Europe Schizophrenia Related Peptide Sales YoY (2017-2028) & (K Units)
Figure 19. Europe Schizophrenia Related Peptide Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Asia-Pacific Schizophrenia Related Peptide Sales YoY (2017-2028) & (K Units)
Figure 21. Asia-Pacific Schizophrenia Related Peptide Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Latin America Schizophrenia Related Peptide Sales YoY (2017-2028) & (K Units)
Figure 23. Latin America Schizophrenia Related Peptide Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Middle East & Africa Schizophrenia Related Peptide Sales YoY (2017-2028) & (K Units)
Figure 25. Middle East & Africa Schizophrenia Related Peptide Revenue YoY (2017-2028) & (US$ Million)
Figure 26. The Schizophrenia Related Peptide Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 27. The Top 5 and 10 Largest Manufacturers of Schizophrenia Related Peptide in the World: Market Share by Schizophrenia Related Peptide Revenue in 2021
Figure 28. Global Schizophrenia Related Peptide Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 29. Global Schizophrenia Related Peptide Sales Market Share by Purity (2017-2028)
Figure 30. Global Schizophrenia Related Peptide Revenue Market Share by Purity (2017-2028)
Figure 31. Global Schizophrenia Related Peptide Sales Market Share by Application (2017-2028)
Figure 32. Global Schizophrenia Related Peptide Revenue Market Share by Application (2017-2028)
Figure 33. North America Schizophrenia Related Peptide Sales Market Share by Purity (2017-2028)
Figure 34. North America Schizophrenia Related Peptide Revenue Market Share by Purity (2017-2028)
Figure 35. North America Schizophrenia Related Peptide Sales Market Share by Application (2017-2028)
Figure 36. North America Schizophrenia Related Peptide Revenue Market Share by Application (2017-2028)
Figure 37. North America Schizophrenia Related Peptide Sales Share by Country (2017-2028)
Figure 38. North America Schizophrenia Related Peptide Revenue Share by Country (2017-2028)
Figure 39. United States Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 40. Canada Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 41. Europe Schizophrenia Related Peptide Sales Market Share by Purity (2017-2028)
Figure 42. Europe Schizophrenia Related Peptide Revenue Market Share by Purity (2017-2028)
Figure 43. Europe Schizophrenia Related Peptide Sales Market Share by Application (2017-2028)
Figure 44. Europe Schizophrenia Related Peptide Revenue Market Share by Application (2017-2028)
Figure 45. Europe Schizophrenia Related Peptide Sales Share by Country (2017-2028)
Figure 46. Europe Schizophrenia Related Peptide Revenue Share by Country (2017-2028)
Figure 47. Germany Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 48. France Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 49. U.K. Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 50. Italy Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 51. Russia Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 52. Asia Pacific Schizophrenia Related Peptide Sales Market Share by Purity (2017-2028)
Figure 53. Asia Pacific Schizophrenia Related Peptide Revenue Market Share by Purity (2017-2028)
Figure 54. Asia Pacific Schizophrenia Related Peptide Sales Market Share by Application (2017-2028)
Figure 55. Asia Pacific Schizophrenia Related Peptide Revenue Market Share by Application (2017-2028)
Figure 56. Asia Pacific Schizophrenia Related Peptide Sales Share by Region (2017-2028)
Figure 57. Asia Pacific Schizophrenia Related Peptide Revenue Share by Region (2017-2028)
Figure 58. China Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 59. Japan Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 60. South Korea Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 61. India Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 62. Australia Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 63. China Taiwan Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 64. Indonesia Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 65. Thailand Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 66. Malaysia Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 67. Latin America Schizophrenia Related Peptide Sales Market Share by Purity (2017-2028)
Figure 68. Latin America Schizophrenia Related Peptide Revenue Market Share by Purity (2017-2028)
Figure 69. Latin America Schizophrenia Related Peptide Sales Market Share by Application (2017-2028)
Figure 70. Latin America Schizophrenia Related Peptide Revenue Market Share by Application (2017-2028)
Figure 71. Latin America Schizophrenia Related Peptide Sales Share by Country (2017-2028)
Figure 72. Latin America Schizophrenia Related Peptide Revenue Share by Country (2017-2028)
Figure 73. Mexico Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 74. Brazil Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 75. Argentina Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 76. Colombia Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 77. Middle East and Africa Schizophrenia Related Peptide Sales Market Share by Purity (2017-2028)
Figure 78. Middle East and Africa Schizophrenia Related Peptide Revenue Market Share by Purity (2017-2028)
Figure 79. Middle East and Africa Schizophrenia Related Peptide Sales Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Schizophrenia Related Peptide Revenue Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Schizophrenia Related Peptide Sales Share by Country (2017-2028)
Figure 82. Middle East and Africa Schizophrenia Related Peptide Revenue Share by Country (2017-2028)
Figure 83. Turkey Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 84. Saudi Arabia Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 85. UAE Schizophrenia Related Peptide Revenue (2017-2028) & (US$ Million)
Figure 86. Schizophrenia Related Peptide Value Chain
Figure 87. Schizophrenia Related Peptide Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed


★調査レポート[統合失調症関連ペプチドの世界市場インサイト・予測（～2028年）] (コード：QY22JLX10486)販売に関する免責事項を必ずご確認ください。
★調査レポート[統合失調症関連ペプチドの世界市場インサイト・予測（～2028年）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • アジュバントペプチドの世界市場インサイト・予測（～2028年）
  • 経口ペプチド薬の世界市場インサイト・予測（～2028年）
  • ガストリン放出ペプチドの世界市場インサイト・予測（～2028年）
  • 注射ペプチド薬の世界市場インサイト・予測（～2028年）
  • タンパク質＆ペプチド治療薬の世界市場インサイト・予測（～2028年）

    • ◆H&Iグローバルリサーチのお客様（例）◆